Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients

References

• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016.
   PubMed Web of Science ®Google Scholar
• Ambinder AJ, Shenoy PJ, Malik N, et al. Exploring risk factors for follicular lymphoma. Adv Hematol. 2012;2012:626035. doi: 10.1155/2012/626035.
   PubMedGoogle Scholar
• Flowers CR, Armitage JO. A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk. 2010;10:414–423.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27:1202–1208.
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program. [cited 2015 Nov 23]. Available from: http://seer.cancer.gov/seerstat/.
   Google Scholar
• Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer (IARC); 2008.
   Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068.
   PubMed Web of Science ®Google Scholar
• Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875–3876.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. 2015 March 10. NCCN Clinical Practice Guidelines in Oncology (Version 2.2015). Available from: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.
   Google Scholar
• Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110:652–659.
   PubMed Web of Science ®Google Scholar
• Wohrer S, Jaeger U, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol. 2006;17:780–784.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG. Imaging follicular lymphoma using positron emission tomography with [(18)F]fluorodeoxyglucose: to what purpose?. J Clin Oncol. 2012;30:4285–4287.
   PubMed Web of Science ®Google Scholar
• Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer. 2001;91:889–899.
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol. 2001;12:825–830.
   PubMed Web of Science ®Google Scholar
• Castellucci P, Nanni C, Farsad M, et al. Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun. 2005;26:689–694.
   PubMed Web of Science ®Google Scholar
• Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647–1649.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–578.
   PubMed Web of Science ®Google Scholar
• Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107:175–183.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Mitchell JM. Utilization trends for advanced imaging procedures: evidence from individuals with private insurance coverage in California. Med Care. 2008;46:460–466.
   PubMed Web of Science ®Google Scholar
• Smith-Bindman R, Miglioretti DL, Larson EB. Rising use of diagnostic medical imaging in a large integrated health system. Health Aff (Millwood). 2008;27:1491–1502.
   PubMed Web of Science ®Google Scholar
• Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:4–18.
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results Program. [cited 2015 Sep 18]. ICD-O-3 SEER Site/Histology validation List. Available from: http://seer.cancer.gov/icd-o-3/sitetype.icdo3.d20150310.pdf.
   Google Scholar
• Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2191–2197.
   PubMed Web of Science ®Google Scholar
• Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–1267.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Sinha R, Byrtek M, et al. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol. 2016;172:724–734.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. [cited 2015 Mar 31]. Available from: http://ahrf.hrsa.gov/overview.htm
   Google Scholar
• The Dartmouth Institute for Health Policy and Clinical Practice. [cited 2015 Jan 31]. The Dartmouth Atlas of Healthcare. Available from: http://www.dartmouthatlas.org/data/region/.
   Google Scholar
• Hadley J, Yabroff KR, Barrett MJ, et al. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst. 2010;102:1780–1793.
   PubMed Web of Science ®Google Scholar
• Wright JD, Ananth CV, Tsui J, et al. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. Cancer. 2014;120:1246–1254.
   PubMed Web of Science ®Google Scholar
• Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ. 2008;27:531–543.
   PubMed Web of Science ®Google Scholar
• Carpenter WR, Reeder-Hayes K, Bainbridge J, et al. The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation. Med Care. 2011;49:172–179.
   PubMed Web of Science ®Google Scholar
• Abou-Nassar KE, Vanderplas A, Friedberg JW, et al. Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leuk Lymphoma. 2013;54:2155–2162.
   PubMed Web of Science ®Google Scholar
• Luminari S, Biasoli I, Arcaini L, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol. 2013;24:2108–2112.
   PubMed Web of Science ®Google Scholar
• Noy A, Schoder H, Gonen M, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20:508–512.
   PubMed Web of Science ®Google Scholar
• Tang B, Malysz J, Douglas-Nikitin V, et al. Correlating metabolic activity with cellular proliferation in follicular lymphomas. Mol Imaging Biol. 2009;11:296–302.
   PubMed Web of Science ®Google Scholar
• Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:5165–5169.
   PubMed Web of Science ®Google Scholar
• Bains P, Al Tourah A, Campbell BA, et al. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Ann Oncol. 2013;24:428–432.
   PubMed Web of Science ®Google Scholar
• Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15:1587–1594.
   PubMed Web of Science ®Google Scholar
• Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157:188–196.
   PubMed Web of Science ®Google Scholar
• Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:2426–2433.
   PubMed Web of Science ®Google Scholar
• Yuen AR, Kamel OW, Halpern J, et al. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol. 1995;13:1726–1733.
   PubMed Web of Science ®Google Scholar
• Wong-Sefidan I, Byrtek M, Zhou X, et al. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leuk Lymphoma. 2016. [Epub ahead of print]. doi: 10.1080/10428194.2016.1213824.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Coverage with Evidence Development. [cited 2015 Mar 31]. Available from: https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/.
   Google Scholar
• Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol. 2012;30:4317–4322.
   PubMed Web of Science ®Google Scholar